| Pharmaceutical Information |
| Drug Name |
Rupatadine |
| Drug ID |
BADD_D02635 |
| Description |
Rupatadine is a dual histamine H1 receptor and platelet activating factor receptor antagonist that is used for symptomatic relief in seasonal and perennial rhinitis as well as chronic spontaneous urticaria. It was approved for marketing in Canada under the tradename Rupall and comes in tablet formulation for adult use and liquid formulation for pediatric use. |
| Indications and Usage |
For the symptomatic relief of nasal and non-nasal symptoms of seasonal allergic rhinitis and perennial allergic rhinitis in patients 2 years of age and older [FDA Label]. Also used for the symptomatic relief of chronic spontaneous urticaria in patients 2 years of age and older. |
| Marketing Status |
approved |
| ATC Code |
R06AX28 |
| DrugBank ID |
DB11614
|
| KEGG ID |
D07407
|
| MeSH ID |
C103639
|
| PubChem ID |
133017
|
| TTD Drug ID |
D0S1CQ
|
| NDC Product Code |
Not Available |
| UNII |
2AE8M83G3E
|
| Synonyms |
rupatadine | 8-chloro-6,11-dihydro-11-(1-((5-methyl-3-pyridinyl)methyl)-4-piperidinylidene)-5H-benzo(5,6)cyclohepta(1,2-b)pyridine | UR 12592 | UR-12592 |
|
| Chemical Information |
| Molecular Formula |
C26H26ClN3 |
| CAS Registry Number |
158876-82-5 |
| SMILES |
CC1=CC(=CN=C1)CN2CCC(=C3C4=C(CCC5=C3N=CC=C5)C=C(C=C4)Cl)CC2 |
| Chemical Structure |
|
|
| ADRs Induced by Drug |
|
|
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
|
|
|
